SLDB

Solid Biosciences Stock Price

8.205
0.235 (2.95%)
Upgrade to Real-Time
Regular Market
8.205
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Solid Biosciences Inc SLDB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.235 2.95% 8.205 13:49:57
Open Price Low Price High Price Close Price Prev Close
8.40 7.62 8.48 7.97
Bid Price Ask Price Spread News
8.18 8.23 0.05 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,737 464,806 $ 8.06 $ 3,748,638 3,342,494 1.93 - 11.58
Last Trade Time Type Quantity Stock Price Currency
13:50:57 1 $ 8.185 USD

Solid Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 695.57M 84.77M 63.19M $ - $ - -2.93 -3.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Solid Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SLDB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.0011.586.659.293,863,0671.2117.21%
1 Month6.5211.586.328.911,477,2801.6925.84%
3 Months3.6211.583.506.722,355,0264.59126.66%
6 Months2.3711.581.934.633,157,6265.84246.2%
1 Year3.3011.581.934.471,683,8804.91148.64%
3 Years28.8454.841.937.39943,685-20.64-71.55%
5 Years25.5054.841.937.58926,123-17.30-67.82%

Solid Biosciences Description

Solid Biosciences Inc is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.


Your Recent History
NASDAQ
SLDB
Solid Bios..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.